Drugmaker Vivus Inc. (NASDAQ:VVUS) said Thursday it has filed a lawsuit against Actavis PLC and its affiliates in a New Jersey federal court over its bid with the U.S. Food and Drug Administration to sell a generic version of company’ prescription weight-loss drug Qsymia. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -0.19% in last session and finished the day at $5.17. Traded volume was 1.03million shares in the last session and the average volume of the stock remained 3.08million shares. The beta of the stock remained 1.41. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.60%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a bio-pharmaceutical company that mainly focuses on discovering, developing as well as commercializing drugs, and primarily targets G protein-coupled receptors.  On June 13, 2014 the major pharmaceutical company announced that it is programmed to present a corporate overview on Wednesday, June 18, 2014. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -1.27 percent to $6.20 Tuesday on volume of 4.30million shares. The intra-day range of the stock was $6.11 to $6.28. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a market capitalization of $1.36billion.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on June 12 announced the pricing of $200 million aggregate principal amount of its 3.625% convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on June 17, 2014 reported a decrease of -1.16% to the closing price of $6.38. Its fifty two weeks range is $2.15 -$23.00. The total market capitalization recorded $1.19billion. The overall volume in the last trading session was 6.30million shares. In its share capital, ARIA has 186.80million outstanding shares.

Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) reached settlement deals with four generic drug companies resolving a patent dispute over the company’s sleep disorder drug Nuvigil. On Tuesday, shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) dropped -0.48% to close the day at $51.45. Company return on investment (ROI) is 4.90% and its monthly performance is recorded as 3.29%. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) quarterly revenue growth is 3.81%.

US biotech firm Biogen Idec Inc. (NASDAQ:BIIB) and US drugmaker AbbVie (NYSE: ABBV) have announced positive top-line results from the Phase III DECIDE clinical trial, evaluating the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular interferon beta-1a (IFN beta-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS). Biogen Idec Inc (NASDAQ:BIIB) stock performance was -1.03% in last session and finished the day at $304.79. Traded volume was 862,056.00million shares in the last session and the average volume of the stock remained 1.60million shares. The beta of the stock remained 1.21. Biogen Idec Inc (NASDAQ:BIIB) insider ownership is 0.10%.